June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Interim Analyses of the SAVE-2 Study:irolimus as a Therapeutic Approach for UVEitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients with Non-infectious Uveitis
Author Affiliations & Notes
  • Yasir Jamal Sepah
    University of Nebraska Medical Center, Omaha, MA
  • Mohammad Ali Sadiq
    University of Nebraska Medical Center, Omaha, MA
  • Mohamed Kamel Soliman
    University of Nebraska Medical Center, Omaha, MA
    Ophthalmology, Assiut University, Assiut, Egypt
  • Mohamed Ibrahim
    University of Nebraska Medical Center, Omaha, MA
  • Mostafa Saad Hanout
    University of Nebraska Medical Center, Omaha, MA
  • Salman Sarwar
    University of Nebraska Medical Center, Omaha, MA
  • Aniruddha Agarwal
    University of Nebraska Medical Center, Omaha, MA
  • Diana V Do
    University of Nebraska Medical Center, Omaha, MA
  • Quan Dong Nguyen
    University of Nebraska Medical Center, Omaha, MA
  • Footnotes
    Commercial Relationships Yasir Sepah, None; Mohammad Sadiq, None; Mohamed Soliman, None; Mohamed Ibrahim, None; Mostafa Hanout, None; Salman Sarwar, None; Aniruddha Agarwal, None; Diana Do, None; Quan Dong Nguyen, Santen (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5775. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yasir Jamal Sepah, Mohammad Ali Sadiq, Mohamed Kamel Soliman, Mohamed Ibrahim, Mostafa Saad Hanout, Salman Sarwar, Aniruddha Agarwal, Diana V Do, Quan Dong Nguyen, ; Interim Analyses of the SAVE-2 Study:irolimus as a Therapeutic Approach for UVEitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients with Non-infectious Uveitis. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5775.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To report the interim analyses of the efficacy of 2 different doses of intravitreal (IVT) sirolimus in eyes with non-infectious posterior, intermediate, or panuveitis in the SAVE-2 Study at the primary endpoint.

 
Methods
 

SAVE-2 is a randomized, phase 2, open-label study conducted at 3 clinical centers in the United States. At least 28, but not more than 32, subjects are to be enrolled. Key inclusion criteria were: 1) diagnosis of non-infectious uveitis; 2) active uveitis, defined as having at least 1+ vitreous haze (NEI scale) and/or at least 1+ vitreous cell count (SUN scale); 3) best-corrected ETDRS visual acuity of 20/400 or better in the study eye. Eligible subjects were randomized into one of two treatment arms in a ratio of 1:1. Group 1 received IVT 440 µg of sirolimus in study eyes on Days 0, 30, 60, 90, 120, and 150; group 2 received 880 µg of sirolimus on Days 0, 60, and 120. Fellow eyes are also eligible to receive sirolimus (of opposite dose to that of study eye) in SAVE-2. Primary endpoint of the study is at M6. Starting at M6, both study and fellow eyes can be retreated based on retreatment criteria with originally assigned doses. Patients are followed until M12.

 
Results
 

25 subjects have been randomized in SAVE-2 and are included in the analysis. Baseline characteristics are shown in Table. Vitreous haze (VH) decreased (M6 compared to baseline) by 1 step or more in 81.8% and 92.9% of patients in group 1 (low dose) and 2 (high dose), respectively at M6 (p=0.564). VH decreased by 2 steps or more in 63.6% and 50% of patients in groups 1 and 2, respectively at M6 (p=0.695). Mean change in VA for subjects who completed M6 visit was +3.66 and -2.91 ETDRS letters in group 1 and 2, respectively. Among subjects with macular edema at baseline (n=13), the mean change in foveal thickness was -89.42 µm in group 1 and +81.5 µm in group 2 at M6.

 
Conclusions
 

Both low and high doses of IVT sirolimus are found to decrease vitreous haze in eyes with non-infectious uveitis. Low dose (440 µg) sirolimus administered monthly may be more efficacious in reducing uveitic macular edema than high dose (880 µg) administered every 2 months.  

 
Table - Baseline Characteristics of Subjects in the SAVE-2 Study
 
Table - Baseline Characteristics of Subjects in the SAVE-2 Study

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×